BCR-ABL and the Philadelphia Chromosome: — TKI Treatment for CML

Imatinib remains a standard and effective first-line option for most patients with BCR-ABL positive CML. Second-generation TKIs such as dasatinib and nilotinib produce deeper responses more quickly in some patients, which is why some oncologists choose them when a faster deep response matters for a particular situation. European LeukemiaNet guidance accepts both first- and second-generation TKIs as valid starting choices; the decision depends on your response goals, the side-effect profile of each drug, and any other conditions you have. Ask your oncologist to explain the reasoning behind the drug they recommend for your case.

Generic imatinib contains the same active molecule as the original branded version and is regulated by CDSCO in India to the same standards. The clinical evidence supports that it works in the same way. If you are switched from one brand to another, your oncologist will continue monitoring your PCR result to confirm your response stays stable. If you notice a change in how a tablet looks or feels when your brand changes, mention it to your team — but do not stop taking it without speaking to them first.

For many patients, TKI treatment is long-term, and stopping without medical supervision is not safe — BCR-ABL levels rise quickly in most cases when treatment stops. However, in a proportion of patients who achieve and sustain a deep molecular response, European LeukemiaNet guidance describes a supervised trial of stopping, called treatment-free remission. This is only considered after years of stable deep response, requires very frequent monitoring after stopping, and is not suitable for everyone. It is a goal to work toward with your team, not a decision to make independently.

A rising BCR-ABL level is called a loss of response. The first thing your oncologist will check is whether missed doses are the cause, because inconsistent tablet-taking is the most common reason. If adherence is confirmed, a test for resistance mutations is done to find out whether the BCR-ABL protein has changed in a way that stops the current TKI from working. If a resistance mutation is identified, switching to a TKI that can overcome that specific mutation is the usual next step. A rising level caught through regular monitoring is manageable — which is exactly what the three-monthly PCR testing is designed to catch.

Bone marrow transplant was the main treatment for CML before TKIs became available. Today it is reserved for a small minority of patients — those in whom multiple TKIs have failed, those who have progressed to a more advanced phase called blast crisis, or those with specific resistance mutations for whom no further TKI is effective. It carries significant risks and is not a first-choice option for most patients with BCR-ABL positive CML. Your oncologist will tell you clearly if it applies to your situation.

Most TKIs are not considered safe during pregnancy, and some are contraindicated throughout. This applies both to women who may become pregnant and to men whose partners may become pregnant, as some TKIs can affect a developing embryo. If you are of reproductive age, tell your oncologist before treatment begins so the plan can account for this. If pregnancy is planned, there are approaches that some oncologists manage in specialist centres — but they require careful planning well in advance. Do not make decisions about contraception or fertility without discussing them with your team first.